June 16, 2024

The U.S. Naloxone Market is driven by growing opioid overdose cases.

Naloxone is an opioid antagonist medication used to counter the effects of opioid overdose such as heroin or prescription pain medications. It works by blocking the effects of opioids and can rapidly reverse an overdose if given in time. The rising prevalence of opioid abuse disorders in the U.S. has heightened the need for naloxone-based drugs and formulations such as nasal sprays, auto-injectors and intramuscular injections that can be administered without medical expertise in emergency situations. Easy availability of naloxone through community-based programs and first responders have helped save thousands of lives from opioid overdose annually. However, frequent relapses and recurring overdoses mean the demand remains high.

The global U.S. Naloxone Market is estimated to be valued at US$ 1,390.7 Mn in 2024 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends: One of the key trends in the U.S. Naloxone Market is the launch and adoption of naloxone auto-injectors and nasal spray formulations. Prefilled syringes and easy-to-administer nasal sprays reduce the complexity of emergency administration during opioid overdoses when every second counts. Devices like Evzio by Kaleo which provide voice instructions have gained popularity. Similarly, intranasal naloxone products such as Narcan nasal spray by Adapt Pharma require minimal training and are suitable for layperson use. This has increased accessibility to life-saving treatment in community settings and empowered bystanders and family members to respond to overdoses.

Porter’s Analysis
Threat of new entrants: Low. Established prescription drug regulations present barriers for new players to enter the U.S. naloxone market.

Bargaining power of buyers: Moderate. Large buyers like governments and healthcare facilities can negotiate lower prices for naloxone products.

Bargaining power of suppliers: Low. There are many established suppliers for naloxone drug manufacturers.

Threat of new substitutes: Low. No major substitute available for naloxone which specifically treats opioid overdose.

Competitive rivalry: High. Key players like Mylan N.V., Novartis AG faces competition based on new product approvals, pricing and marketing strategies.

Key Takeaways

The global U.S. Naloxone market is expected to witness high growth.

Regional analysis comprises the U.S. represents the largest market for naloxone currently and is expected to dominate the market over the forecast period due to growing opioid addiction and rising rates of overdose cases in the region.

Key players operating in the U.S. Naloxone market are Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., Kern Pharma, S.L., Samarth Life Sciences Pvt. Ltd., Opiant Pharmaceuticals, Pfizer, Sandoz, and Amneal Pharmaceuticals. Mylan N.V. leads the market currently with its naloxone autoinjector Evzio.


  1. Source: Coherent Market Insights, Public sources, Desk research

2. We have leveraged AI tools to mine information and compile it